Skip to content
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
  • Investors & Media
  • Contact Us
  • Investors & Media
  • Contact Us
Ironwood Pharmaceuticals Logo
Ironwood Pharmaceuticals
Close
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions

Year: 2014

Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-IIa-Clinical-Study-of-IW-9179-in-Diabetic-Gastroparesis/default.aspx

Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-IIa-Clinical-Study-of-IW-9179-in-Diabetic-Gastroparesis/default.aspx

Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Earns-15-Million-Milestone-from-Astellas-upon-Initiation-of-Enrollment-in-Linaclotide-Phase-III-IBS-C-Clinical-Trial-in-Japan/default.aspx

Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Earns-15-Million-Milestone-from-Astellas-upon-Initiation-of-Enrollment-in-Linaclotide-Phase-III-IBS-C-Clinical-Trial-in-Japan/default.aspx

Ironwood Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-2014-Healthcare-Conference/default.aspx

Ironwood Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-2014-Healthcare-Conference/default.aspx

Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2014-Investor-Update/default.aspx

Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-III-Trial-of-72-mcg-Linaclotide-in-Adult-Patients-with-Chronic-Idiopathic-Constipation/default.aspx

Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2014-Investor-Update/default.aspx

Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation

https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-III-Trial-of-72-mcg-Linaclotide-in-Adult-Patients-with-Chronic-Idiopathic-Constipation/default.aspx

Next →
Ironwood Pharmaceuticals Home
  • Investors & Media
  • Contact Us
Linkedin Twitter
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
  • Copyright © 2024 Ironwood. All rights reserved
  • Privacy Policy
  • Terms of Use
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
    • Investors & Media
    • Contact Us